Announced Fri, 26 Jun · 14:35 IST
Marksans Pharma resubmits FY26 results in readable format
Compliance View source PDF
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.1%1-day move
₹258.00
prior close
₹256.09
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.9+0.9+1.1+2.5+7.1+3.9+3.6+2.6+0.8+2.3+3.3———
Up moveDown movePending
AI summary
Marksans Pharma resubmitted its audited Q4 and FY26 financial results in machine readable format after NSE flagged the May 26 filing as not legible. Standalone FY26 revenue rose 14% to Rs 1,341.48 crore, PAT up 60% at Rs 300.70 crore. Q4 standalone PAT surged 144% to Rs 91.92 crore. Consolidated FY26 revenue grew 12.5% to Rs 2,950.94 crore. Final dividend of Rs 0.90 per share recommended.
Likely market impact
Strong FY26 earnings growth; Rs 0.90/share final dividend. Resubmission is purely administrative with no change in numbers.